Cryopreserved ampule of Rat Neonatal Retinal Cells containing ≥200,000 cells
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 10 Million
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing 10 million cells
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 25 million cells
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 1 million cells
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 5 million cells
Cryopreserved ampule of Pulmonary Artery Smooth Muscle Cells (PASMC) containing ≥ 500,000 cells
For efficient transfection of specific primary cells, e.g. human T cells, CD34 or rat neurons, in the 4D-NucleofectorTM X Unit (100 µL format).
Do you need a quote right away? Add this product to your shopping cart, go to your cart and click on “Generate Quote”. Your quote will be available straight away to view, save online, and download in PDF format.
-
Natural Killer Cells InfographicNatural Killer cells have an innate ability to recognize and destroy non-self cells.
-
3D Natural Killer Cell-mediated Cytotoxicity AssayLonza White Paper
-
3D Natural Killer (NK) Cell-mediated Cytotoxicity (CMC) Assay
-
Natural Killer (NK) Cell Expansion, Activation and Cytotoxicity AssayProtocol instructions
-
Therapeutic Approaches to Enhance Natural Killer Cell Cytotoxicity: The Force AwakensPoster published by Nature Reviews Drug Discovery, sponsored by Lonza. Natural killer (NK) cells are emerging as attractive candidates for new immunotherapeutic approaches. The poster shows the approaches to NK cell tumor targeting.
-
Transfection Protocol for Human NK Cells - Nucleofector™ I/II/2b Device SeriesInstructions of use for transfection of human natural killer cells with Nucleofector™ 1/2 Devices (incl. 1, 2b, 2N, 2S)
-
An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cellsA strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells.
-
NK Cell Assay using 3D Bioprinted Tumor ModelsThis white paper describes an ex vivo assay for NK cell killing activity in a 3D bioprinted cervical cancer tumor model.
-
TechSheet - Poietics™ Human Immune System CellsTechnical Product Information Sheet
-
CAR T cells in Cancer TherapyA poster developed by Nature Reviews in conjunction with Lonza to present CAR T cells in cancer therapy. This poster demonstrates the recognition of tumor peptides by T cells, CAR T cell manufacturing, the types of chimeric antigen receptors and a timeline of CAR development over more than 30 years.